Shares of Cytokinetics Inc. (NASDAQ:CYTK) traded down 1.8% on Monday . The stock traded as low as $10.11 and last traded at $10.14, with a volume of 94,192 shares. The stock had previously closed at $10.33.

Several analysts have weighed in on the stock. FBR & Co reiterated a “buy” rating on shares of Cytokinetics in a research note on Monday, May 2nd. Zacks Investment Research upgraded shares of Cytokinetics from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Wednesday, June 29th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $24.00 price objective on shares of Cytokinetics in a research note on Tuesday. Finally, Roth Capital reiterated a “buy” rating on shares of Cytokinetics in a research note on Saturday, April 30th. Eight investment analysts have rated the stock with a buy rating, Cytokinetics currently has a consensus rating of “Buy” and a consensus target price of $17.38.

The company’s market cap is $393.44 million. The stock’s 50 day moving average is $8.90 and its 200 day moving average is $7.96.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.06. On average, equities research analysts anticipate that Cytokinetics Inc. will post ($1.50) earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the company. Russell Frank Co purchased a new stake in shares of Cytokinetics during the fourth quarter worth about $4,719,000. EAM Investors LLC purchased a new stake in shares of Cytokinetics during the fourth quarter worth about $4,388,000. Matarin Capital Management LLC purchased a new stake in shares of Cytokinetics during the fourth quarter worth about $2,512,000. Finally, GSA Capital Partners LLP increased its stake in shares of Cytokinetics by 532.5% in the fourth quarter. GSA Capital Partners LLP now owns 117,931 shares of the biopharmaceutical company’s stock worth $1,234,000 after buying an additional 99,287 shares during the last quarter.

Cytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.